Current Landscape in Medullary Thyroid Cancer: Updates for Clinicians
This program addresses recent changes in standard treatment of MTC that have been identified as areas of knowledge and clinical practice gaps and are directly relevant to the daily practice of healthcare professionals managing patients with MTC. This symposium will provide education on:
- Updated management guidelines
- Preoperative recognition of MTC
- New understanding of RET mutations
- Surgical controversies in MTC
- Management options for advanced and metastatic MTC
This CME activity has been designated to meet the educational needs of physicians and other healthcare professionals directly involved in the management of patients with Medullary Thyroid Cancer.
After completion of this program, participants will be able to
- Discuss current management guidelines for MTC, including surveillance of patients with MTC
- Discuss measures to assess risk in patients with MTC
- Assess for pheochromocytoma and hyperparathyroidism in patients with MTC
- Review recent advanced in cytology in MTC
- Review recent research into RET mutations in MTC
- Discuss the potential impact of RET mutations on treatment decisions
- Review the indications for thyroidectomy in MTC and discuss the role of prophylactic thyroidectomy in hereditary syndromes associated with MTC
- Review assessment of MTC and discuss treatment decisions by extent of disease
- Discuss clinical course of MTC and risk of persistent or recurrent disease
- Review results of recent clinical trials of tyrosine kinase inhibitors in MTC and the potential role of these targeted agents in advanced, progressing MTC
The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is supported by an independent educational grant from Sanofi Genzyme
- 1.75 AMA
- 1.75 Attendance